Drugmakers Roche and Sanofi's latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming "patent cliff" for Big Pharma. Both companies' stocks were down less than 1% on Thursday after reporting earnings before the bell. They are both among the pharmaceutical companies that could see revenue fall dramatically in the coming years unless they top up their pipelines by developing drugs internally or acquiring drug candidates

Tag-uri: Roche